Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Ordinary Shares, nominal value EUR0.04 per share
-
Shares outstanding
-
106,324,269
-
Total 13F shares
-
25,217,186
-
Share change
-
-1,619,759
-
Total reported value
-
$105,911,100
-
Price per share
-
$4.20
-
Number of holders
-
44
-
Value change
-
-$8,198,557
-
Number of buys
-
19
-
Number of sells
-
22
Institutional Holders of ProQR Therapeutics N.V. - Ordinary Shares, nominal value EUR0.04 per share (PRQR) as of Q4 2020
As of 31 Dec 2020,
ProQR Therapeutics N.V. - Ordinary Shares, nominal value EUR0.04 per share (PRQR) was held by
44 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,217,186 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., WELLINGTON MANAGEMENT GROUP LLP, GOLDMAN SACHS GROUP INC, JENNISON ASSOCIATES LLC, DAFNA Capital Management LLC, MORGAN STANLEY, JPMORGAN CHASE & CO, UBS Group AG, and Kerrisdale Advisers, LLC.
This page lists
44
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.